Eating smaller, well-balanced meals throughout the day can support more stable blood sugar levels, prevent energy crashes, and reduce the urge to overeat
What we know: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously Phase 2/3 trials show 24-29% weight loss at highest doses Side effects are similar to other incretin medications (mainly GI) It may be particularly effective for liver fat reduction FDA approval is potentially years away What to consider: Approved alternatives (semaglutide, tirzepatide) have established safety profiles "GLP-3" marketing may oversimplify or mislead Investigational drugs carry unknown long-term risks Quality control for compounded versions is variable Clinical trial results don't always translate to real-world outcomes The bigger picture: Retatrutide may represent a genuine advance in obesity treatmentthe data is genuinely impressive
Lets see what sets this medical weight loss program with GLP-1 medications apart from other weight management solutions available
The organization highlighted the potential of a new real-time biomarker test that assesses the glucose ketone index (GKI) from a blood sample drawn from a finger prick
Chutima Roomruangwong, Chulalongkorn University, Thailand Updates Copyright 2023 da Silva Schmidt, Trettim, Longoni, Grings, de Matos, de Avila Quevedo, Ardais, Nedel, Ghisleni, Leipnitz, Pinheiro and de Assis